Lisata Therapeutics (FRA:8NE) Moat Score: 2/10 (As of Jul. 10, 2026)


FRA:8NE Lisata Therapeutics Inc FRA:8NE
32 GF Score
Price €2.74
! 4 Warning Signs
View Full Analysis

What is Lisata Therapeutics Moat Score?

Lisata Therapeutics FRA:8NE -1.44% 32 Moat Score is 2 as of Jul. 10, 2026. GuruFocus rates FRA:8NE with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,395 Biotechnology companies, Lisata Therapeutics ranks better than 58.35% on this metric.

Lisata Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Lisata Therapeutics has No Moat: Lisata Therapeutics Inc lacks significant market leadership or durable competitive advantages. The company does not exhibit strong brand strength, significant customer switching costs, or valuable intellectual property that would provide a sustainable edge over competitors.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Lisata Therapeutics might have No Moat - Very weak/transient advantages.

Lisata Therapeutics  (FRA:8NE) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Lisata Therapeutics Moat Score Related Terms

FRA:8NE vs SGMO, NNVC, LITS: Moat Score Comparison

For the Biotechnology subindustry, Lisata Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lisata Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Moat Score falls into.


FRA:8NE
32GF Score
Lisata Therapeutics Inc FRA:8NE
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Lisata Therapeutics (FRA:8NE) has a Moat Score of 2 as of Jul. 10, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Lisata Therapeutics ranks #581 out of 1395 companies in the Biotechnology industry, placing it in the top 41.6%.
Is Lisata Therapeutics' Moat Score too high?
Lisata Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Lisata Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Lisata Therapeutics ranks #581 out of 1395 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lisata Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Lisata Therapeutics' Moat Score compare to SGMO and NNVC?
According to the Biotechnology industry distribution chart, Lisata Therapeutics ranks #581 out of 1395 companies for Moat Score. This puts Lisata Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Lisata Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lisata Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lisata Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lisata Therapeutics stock overvalued right now?
Lisata Therapeutics (FRA:8NE) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Lisata Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Lisata Therapeutics (FRA:8NE), the current Moat Score is 2 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lisata Therapeutics Business Description

Other Exchanges LSTA:USA0HS8:UK
Address 110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
32GF Score

Get the complete analysis for FRA:8NE

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.74
Price